The impact of primary gleason grade on biochemical outcome following brachytherapy for hormone-naive gleason score 7 prostate cancer

Cancer Journal

Volumn 11, Issue 3, 2005, Pages 234-240

  Merrick, Gregory S ^a   Butler, Wayne M ^a   Wallner, Kent E ^b   Galbreath, Robert W ^a,c   Allen, Zachariah A ^a   Adamovich, Edward ^d  

^a WHEELING HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ohio University Eastern   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Biochemical outcome; Brachytherapy; Gleason score 7; Prostate cancer

Indexed keywords

ANDROGEN; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INTERSTITIAL RADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RISK ASSESSMENT; SMOKING; SURVIVAL RATE; TUMOR BIOPSY; BLOOD; BRACHYTHERAPY; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 27144448869     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200505000-00010     Document Type: Article

References (29)

1. Herman CM, Kattan MW, Ohori M et al. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer. Am J Surg Pathol 2001;25:657-660.
2. Roehl KA, Han M, Ramos CG et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-914.
3. Tefilli MV, Gheiler EL, Tiguert R et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 1999;53:372-377.
4. Blasko JC, Grimm PD, Sylvester JE et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
5. Merrick GS, Butler WM, Wallner KE et al. The impact of supplemental external beam radiation and/or androgen deprivation therapy on biochemical outcome following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61:32-43.
6. Chan TY, Partin AW, Walsh PC et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-827.
7. Sakr WA, Tefilli MV, Grignon DJ et al. Gleason score 7 prostate cancer: a heterogenous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000;56:730-734.
8. Potters L, Purrazzella R, Brustein S et al. The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:749-754.
9. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
10. D'Amico AV, Renshaw AA, Schultz D et al. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA ≤ 10 ng/mL and T1c,2a: implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys 1999;45:847-851.
11. Groll R, Fleshner NE, Sugar L et al. Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology 2002;59:551-554.
12. Merrick GS, Butler WM, Galbreath RW et al. Biochemical outcome for hormone-naïve patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002;60:98-103.
13. Anderson PR, Hanlon AL, Horwitz E et al. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treatment with three-dimensional conformal external beam radiation therapy. Cancer 2000;89:2565-2569.
14. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
15. Amling CL, Bergstralh EJ, Blute ML et al. Defining prostate-specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146-1151.
16. Merrick GS, Butler WM, Wallner KE et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754-759.
17. Merrick GS, Butler WM, Farthing WH et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int 1998;14:113-121.
18. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: recommendations from the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-234.
19. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design and evaluation. Tech Urol 2000;6:78-84.
20. Merrick GS, Butler WM, Dorsey AT et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 2000;46:215-220.
21. Merrick GS, Butler WM, Wallner KE et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 2003;26:E178-E189.
22. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland [review article]. J Urol 2003;169:1643-1652.
23. Theodorescu D, Frierson HF, Sikes RA. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. J Urol 1999;161:1442-1448.
24. Valicenti R, Lu J, Pilepich M et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trials. J Clin Oncol 2000;18:2740-2746.
25. Martinez AA, Gustafson G, Gonazalez J et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-327.
26. Do TM, Parker RG, Smith RB et al. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001;57:1121-1127.
27. Merrick GS, Butler WM, Dorsey AT et al. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 2001;7:233-240.
28. Davis BJ, Pisansky TM, Wilson TM et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999;85:2630-2637.
29. Sohayda C, Kupelian PA, Levin HS et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000;55:382-386.